These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 8147160)

  • 1. [Initial experience with mycophenolate mofetil (RS 61443) after kidney transplantation].
    Friedrich J; Erhard J
    Zentralbl Chir; 1994; 119(1):48-9. PubMed ID: 8147160
    [No Abstract]   [Full Text] [Related]  

  • 2. [Mycophenolic acid: a welcome adjunct immunosuppressant after organ transplants].
    van Gelder T; Gregoor PJ; Hené RJ; De Sévaux RG; Hilbrands LB
    Ned Tijdschr Geneeskd; 1998 Jul; 142(27):1550-4. PubMed ID: 9763828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppression with mycophenolic acid: one size does not fit all.
    Bennett WM
    J Am Soc Nephrol; 2003 Sep; 14(9):2414-6. PubMed ID: 12937322
    [No Abstract]   [Full Text] [Related]  

  • 4. [Mycophenolate mofetil].
    Abramowicz D; Broeders N; Wissing M; Sternon J
    Rev Med Brux; 1998 Jun; 19(3):139-43. PubMed ID: 9697397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation.
    Taylor DO; Ensley RD; Olsen SL; Dunn D; Renlund DG
    J Heart Lung Transplant; 1994; 13(4):571-82. PubMed ID: 7947873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil-based immunosuppressive minimization and withdrawal strategies in renal transplantation: possible risks and benefits.
    Meier-Kriesche HU
    Curr Opin Nephrol Hypertens; 2006 Jun; 15 Suppl 1():S1-5. PubMed ID: 16829733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enteric coating of mycophenolate reduces dosage adjustments.
    Brister K; Yau CL; Slakey D
    Transplant Proc; 2009 Jun; 41(5):1657-9. PubMed ID: 19545702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RS-61443 reverses acute renal allograft rejection in dogs.
    Platz KP; Bechstein WO; Eckhoff DE; Hullett DA; Sollinger HW
    Transpl Int; 1992; 5 Suppl 1():S542-3. PubMed ID: 14621871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mycophenolate mofetil in renal transplantation].
    Uchida K
    Nihon Rinsho; 2005 May; 63 Suppl 5():684-91. PubMed ID: 15954430
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of mycophenolate mofetil on hematocrit after renal transplantation.
    Chenhsu RY; Wu YM; Min DI; Zimmerman MB
    Ann Pharmacother; 2002 Sep; 36(9):1479-80. PubMed ID: 12196073
    [No Abstract]   [Full Text] [Related]  

  • 11. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee--Japan.
    Takahashi K; Ochiai T; Uchida K; Yasumura T; Ishibashi M; Suzuki S; Otsubo O; Isono K; Takagi H; Oka T
    Transplant Proc; 1995 Feb; 27(1):1421-4. PubMed ID: 7878933
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience.
    Kirklin JK; Bourge RC; Naftel DC; Morrow WR; Deierhoi MH; Kauffman RS; White-Williams C; Nomberg RI; Holman WL; Smith DC
    J Heart Lung Transplant; 1994; 13(3):444-50. PubMed ID: 8061021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacement of calcineurin inhibitors by mycophenolate mofetil: effect on hemoglobine levels.
    Suwelack B; Kobelt V; Hillebrand U; Gerhardt U; Matzkies F; Hohage H
    Transplant Proc; 2002 Aug; 34(5):1808-9. PubMed ID: 12176585
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of mycophenolate mofetil (Cellcept) in renal transplantation.
    Vanrenterghem Y
    Contrib Nephrol; 1998; 124():64-9; discussion 69-75. PubMed ID: 9761975
    [No Abstract]   [Full Text] [Related]  

  • 15. Mycophenolate mofetil: a unique immunosuppressive agent.
    Hood KA; Zarembski DG
    Am J Health Syst Pharm; 1997 Feb; 54(3):285-94. PubMed ID: 9028422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mycophenolate mofetil, a possible new immunosuppresant].
    Weberová J; Voboril R; Semecký V
    Ceska Slov Farm; 2002 Sep; 51(5):220-5. PubMed ID: 12407919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil.
    Lipsky JJ
    Lancet; 1996 Nov; 348(9038):1357-9. PubMed ID: 8918281
    [No Abstract]   [Full Text] [Related]  

  • 19. [The value of mycophenolate mofetil in kidney transplantation. Joint Symposium of the Dutch Society of Nephrology, the German Society of Nephrology and the German Working Group for Clinical Nephrology. Aachen, 8 September 1997].
    Dtsch Med Wochenschr; 1997 Nov; 122(47 Suppl):1-6. PubMed ID: 9431325
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of mycophenolate mofetil on the Anti-CMV serologic response after renal transplantation.
    Hardwick LL; Savatta SG; Book BK; Milgrom ML; McQueen J; Anderson M; Filo RS; Leapman SB; Pescovitz MD
    Transplant Proc; 2001; 33(1-2):1865-6. PubMed ID: 11267545
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.